Viking Therapeutics Inc
Common Stock · EUR · F
Price
€26.388
Cap
€245.71B
Earnings
—
30d Trend
-8.7%
57% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 42×Macro 0.99 (−1%)=42
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Viking Therapeutics Inc at 42/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 56/100. I classify this as a income position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-2.3%
3 MONTHS
-6.4%
12 MONTHS
+16.7%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Momentum (56) and Technical (45) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 57%. I classify this as an income position — the 17.0% yield combined with the dividend profile makes it suitable for income generation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.
